Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment
Por:
Sanchis-Artero L, Martínez-Blanch JF, Manresa-Vera S, Cortés-Castell E, Valls-Gandia M, Iborra M, Paredes-Arquiola JM, Boscá-Watts M, Huguet JM, Gil-Borrás R, Rodríguez-Morales J and Cortés-Rizo X
Publicada:
11 may 2021
Ahead of Print:
11 may 2021
Categoría:
Multidisciplinary
Resumen:
Intestinal dysbiosis is key in the onset and development of Crohn's disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these changes with the microbiota of healthy subjects. This prospective multicenter observational study involved 27 CD patients initiating anti-TNF treatment and 16 healthy individuals. Inflammatory activity was determined at baseline, 3 and 6 months, classifying patients into responders and non-responders. Fecal microbiota was analyzed by massive genomic sequencing thought 16S rRNA amplicon sequencing before and after six months of anti-TNF treatment. The CD cohort showed a decrease in genera of the class Clostridia, short-chain fatty acid producers, and an increase in the phylum Proteobacteria (p<0.01) versus the healthy cohort. After anti-TNF treatment, the phylum Proteobacteria also increased in non-responders versus responders (13/27) (p<0.005), with the class Clostridia increasing. In addition, alpha diversity increased in responders versus non-responders (p<0.01), tending towards eubiosis. An association was found (p<0.001) in the F.prausnitzii/E.coli ratio between responders and non-responders. The F/E ratio was the most accurate biomarker of anti-TNF response (area under the curve 0.87). Thus, anti-TNF treatment allows partial restoration of intestinal microbiota in responders and the F.prausnitzii/E.coli ratio can provide a reliable indicator of response to anti-TNF in CD.
Filiaciones:
:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Sagunto Hospital, Av. Ramón y Cajal S/N, 46520, Sagunto, Valencia, Spain.
Martínez-Blanch JF:
ADM-Lifesequencing S.L., University of Valencia Science Park, Carrer del Catedràtic Agustín Escardino Benlloch 9, Edificio 2, 46980, Paterna, Valencia, Spain.
Department of preventive medicine, public health, food sciencs, toxicology and forensic medicine, Universitat de Valencia, Valencia, Spain.
Manresa-Vera S:
ADM-Lifesequencing S.L., University of Valencia Science Park, Carrer del Catedràtic Agustín Escardino Benlloch 9, Edificio 2, 46980, Paterna, Valencia, Spain
Cortés-Castell E:
Department of Pharmacology, Pediatrics and Organic Chemistry, Miguel Hernández University, Carretera de Valencia-Alicante S/N, 03550, San Juan de Alicante, Alicante, Spain.
:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Hospital General de Castellón, Castellón de la Plana, Spain
Iborra M:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Hospital Universitario y Politécnico La Fe de Valencia, Valencia, Spain
:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Hospital Doctor Peset de Valencia, Valencia, Spain
Boscá-Watts M:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Hospital Clínico Universitario de Valencia, Valencia, Spain
Huguet JM:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Hospital General de Valencia, Valencia, Spain
:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Hospital Lluís Alcanyís de Xàtiva, Valencia, Spain
:
Inflammatory Bowel Disease Unit, Department of Digestive Diseases, Sagunto Hospital, Av. Ramón y Cajal S/N, 46520, Sagunto, Valencia, Spain
Cortés-Rizo X:
Department of Medicine, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain
Green Published, gold
|